Comparative Immune Profiling of Murine and Human Pancreatic Cancer Precursors Reveals Species- and Lesion-Dependent Immune Microenvironments.

Haeberle-Graser L, Schulte M, Mueller C, Haensch S, Schlensog M, Esposito I.

Comparative StudyOpen access

AI summary — for doctors, generated from the abstract only

A detailed immune-mapping study comparing mouse models and human tissue samples of pre-cancerous pancreatic lesions found important differences between species, with human precursor lesions showing early immune changes that the standard mouse models completely missed, cautioning researchers to be careful when translating findings from mouse studies directly to human pancreatic cancer.

What was studied

A comparative study using multiplex immunofluorescence imaging to characterize and compare the immune cell environment across normal tissue, various precursor lesions, and invasive cancer in both a transgenic mouse model (140 samples from 41 mice) and human tissue samples (221 samples from 76 patients) of pancreatic ductal adenocarcinoma.

Key findings

Both mouse and human invasive pancreatic cancer showed an immune-suppressive environment, but the precursor (pre-cancerous) lesions differed markedly between species: mouse precursor lesions showed essentially no increase in immune cell activity compared with normal tissue, while human precursor lesions already showed elevated mast cells, macrophages, helper T cells, and regulatory T cells.
Human precursor lesions and one specific cyst subtype showed a significant increase in cancer-fighting CD8+ cytotoxic T cells compared with normal tissue, which then decreased once the lesion progressed to invasive cancer, while other precursor subtypes (intestinal-type and mucinous cystic lesions) showed no such increase.
These findings indicate that the immune environment evolves differently at different stages of cancer development and differs substantially both between species and between different types of human precursor lesions.

Clinical relevance

The findings caution researchers that mouse models, while useful, do not fully replicate the human immune environment during the earliest stages of pancreatic cancer development, which has important implications for how preclinical research findings (such as potential immune-based prevention or early intervention strategies) should be interpreted and translated toward human patients.

Who should care

Pathology

Limitations

This is a comparative tissue-profiling study rather than a clinical trial, and while differences between species and lesion types were clearly documented, the study does not directly test how these immune differences affect actual patient outcomes or treatment response.

Immune changes in the earliest stages of pancreatic cancer development differ substantially between mouse models and human tissue, with human precursor lesions showing immune activity that standard mouse models completely miss, cautioning researchers about directly translating preclinical mouse findings to human pancreatic cancer.

This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.

Abstract

Purpose

This study aimed to comparatively characterize the immune microenvironment (iME) in murine and human precursor lesions of pancreatic ductal adenocarcinoma (PDAC) to better understand its role in pancreatic carcinogenesis.

Materials and methods

Tissue microarrays were constructed from 41 transgenic mice (140 samples including normal pancreas tissue, acinar-ductal metaplasia [ADM], pancreatic intraepithelial neoplasms [PanIN], and PDAC) and from 76 patients (221 samples including normal pancreas tissue, ADM, PanIN, intraductal papillary mucinous neoplasms [IPMN], mucinous cystic neoplasms [MCN], and PDAC). OPAL7 multiplex immunofluorescence was used for simultaneous detection of multiple immune cell markers (CD3, CD4, CD8, CD8a, FoxP3, PD-1, CD19, CD20, F4/80, CD68, CD163, tryptase, and granzyme B), followed by software-assisted image-based quantification.

Results

The iME of all lesions was characterized by a predominance of CD3+ T lymphocytes over B lymphocytes, except for murine PanIN, which showed CD19+ B cell predominance. Both murine and human PDAC showed an immunosuppressive iME. However, precursor lesions differed markedly: murine ADM and PanIN showed no significant immune cell increases, while human ADM already displayed elevated mast cells, macrophages, T helper cells, and Tregs. Human ADM, PanIN, and gastric-type IPMN showed a significant increase in CD8+ cytotoxic T cells compared with normal pancreas tissue, while cytotoxic T cells were decreased in PDAC. In contrast, human intestinal-type IPMN and MCN showed no increase in cytotoxic T cells.

Conclusions

These findings highlight that the iME evolves during pancreatic carcinogenesis and differs significantly between species and lesion types. The immune landscape of murine models does not fully recapitulate that of human disease, emphasizing the need for caution when translating preclinical findings. Moreover, distinct immune profiles across human precursor subtypes suggest precursor-specific mechanisms of immune engagement.

DOI

10.1016/j.labinv.2026.106143

PMID

42242332

Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.

Want more like this?

Browse more from the feed. A free account unlocks the full feed, saving and communities.

Back to the research feed

Create a free account · Sign in